Cited by 1,134Melanoma and MAPK PathwaysLung Cancer Treatments and MutationsCancer Mechanisms and Therapy

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Open access

Wilson, Timothy R., Fridlyand, Jane, Yan, Yibing, Penuel, Elicia, Burton, Luciana, Chan, Emily, Peng, Jing, Lin, Eva, Wang, Yulei, Sosman, Jeff, Ribas, Antoni, Li, Jiang, Moffat, John, Sutherlin, Daniel P., Koeppen, Hartmut, Merchant, Mark, Neve, Richard, Settleman, Jeff·2012·Nature

DOI 10.1038/nature11249PMC PMC3724525

Open this paper in CoChat — free account

Abstract

Mutationally activated kinases define a clinically validated class of targets for cancer drug therapy. However, the efficacy of kinase inhibitors in patients whose tumours harbour such alleles is invariably limited by innate or acquired drug resistance. The identification of resistance mechanisms has revealed a recurrent theme—the engagement of survival signals redundant to those transduced by the targeted kinase. Cancer cells typically express multiple receptor tyrosine kinases (RTKs) that mediate signals that converge on common critical downstream cell-survival effectors—most notably, phosphatidylinositol-3-OH kinase (PI(3)K) and mitogen-activated protein kinase (MAPK). Consequently, an increase in RTK-ligand levels, through autocrine tumour-cell production, paracrine contribution from tumour stroma or systemic production, could confer resistance to inhibitors of an oncogenic kinase with a similar signalling output. Here, using a panel of kinase-'addicted' human cancer cell lines, we found that most cells can be rescued from drug sensitivity by simply exposing them to one or more RTK ligands. Among the findings with clinical implications was the observation that hepatocyte growth factor (HGF) confers resistance to the BRAF inhibitor PLX4032 (vemurafenib) in BRAF-mutant melanoma cells. These observations highlight the extensive redundancy of RTK-transduced signalling in cancer cells and the potentially broad role of widely expressed RTK ligands in innate and acquired resistance to drugs targeting oncogenic kinases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature11249

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Friends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1477 · Cited by 1,817
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Self-citation
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059

Flagged first, then by citations

Show all 29 references

Sorted by citations

Items 601–700 of 1,000

Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model
Curley, M. D., Sabnis, G. J., Wille, L., Adiwijaya, B. S., García, G., Moyo, V. M., Kazi, A. A., Brodie, A., & MacBeath, G. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0169 · Cited by 28
Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
Kang, J. C., Poovassery, J. S., Bansal, P., You, S., Manjarrés, I. M., Ober, R. J., & Ward, E. S. (2013) · mAbs · doi:10.4161/mabs.27658 · Cited by 31
Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy
Belizário, J. E., Sangiuliano, B. A., Pérez-Sosa, M., Neyra, J. M., & Moreira, D. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00312 · Cited by 28
Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
Fujimura, T., Fujisawa, Y., Kambayashi, Y., & Aiba, S. (2019) · Cancers · doi:10.3390/cancers11091342 · Cited by 28
The utility of transposon mutagenesis for cancer studies in the era of genome editing
DeNicola, G. M., Karreth, F. A., Adams, D. J., & Wong, C. C. (2015) · Genome biology · doi:10.1186/s13059-015-0794-y · Cited by 30
Evolution of targeted therapies in cancer: opportunities and challenges in the clinic
Santhosh, S., Kumar, P. R. G., Ramprasad, V. L., & Chaudhuri, A. (2015) · Future Oncology · doi:10.2217/fon.14.198 · Cited by 29
Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma
Wang, J., Chen, J., Miller, D. D., & Li, W. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0212 · Cited by 29
The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET -Amplified Cancer
Égile, C., Kenigsberg, M., Delaisi, C., Bégassat, F., Do-Vale, V., Mestadier, J., Bonche, F., Bénard, T., Nicolas, J., Valence, S., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0428 · Cited by 29
Targeting breast cancer through its microenvironment: Current status of preclinical and clinical research in finding relevant targets
Nienhuis, H. H., Gaykema, S. B. M., Timmer‐Bosscha, H., Jalving, M., Brouwers, A. H., Hooge, M. N. L., van der Vegt, B., Overmoyer, B. A., de Vries, E. G. E., & Schroder, C. P. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.004 · Cited by 29
The Role of Tumor Microenvironment in Melanoma Therapy Resistance
Somasundaram, R., Herlyn, M., & Wagner, S. N. (2016) · Melanoma Management · doi:10.2217/mmt.15.37 · Cited by 30
A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem–Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy
Luraghi, P., Bigatto, V., Cipriano, É., Reato, G., Orzan, F., Sassi, F. P., Bacco, F. D., Isella, C., Bellomo, S. E., Médico, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2151 · Cited by 28
Cancer-associated fibroblasts: Recent developments and emerging challenges
Östman, A. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.02.004 · Cited by 28
The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance
Fromme, J. E., & Zigrino, P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.864302 · Cited by 27
Progress towards personalized medicine for ameloblastoma
Gomes, C. C., Diniz, M. G., & Gomez, R. S. (2014) · The Journal of Pathology · doi:10.1002/path.4331 · Cited by 27
Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain
Miller, M. A., Moss, M. L., Powell, G., Petrovich, R. M., Edwards, L. L., Meyer, A. S., Griffith, L. G., & Lauffenburger, D. A. (2015) · Scientific Reports · doi:10.1038/srep15150 · Cited by 28
Targeting c‐ M et in Cancer by Micro RNA s: Potential Therapeutic Applications in Hepatocellular Carcinoma
Karagonlar, Z. F., Korhan, P., & Atabey, N. (2015) · Drug Development Research · doi:10.1002/ddr.21274 · Cited by 27
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine
Chappell, W. H., Abrams, S. L., Franklin, R. A., LaHair, M. M., Montalto, G., Cervello, M., Martelli, A. M., Nicoletti, F., Candido, S., Libra, M., et al. (2012) · Cell Cycle · doi:10.4161/cc.22786 · Cited by 27
Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy
Li, C.-F., He, H.-L., Wang, J., Huang, H.-Y., Wu, T., Hsing, C., Lee, S.-W., Lee, H.-H., Fang, J.-L., Huang, W.-T., et al. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202551 · Cited by 30
Durability of Kinase-Directed Therapies—A Network Perspective on Response and Resistance
Murray, B. W., & Miller, N. L. G. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0088 · Cited by 27
Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer
Mohyeldin, M. M., Busnena, B. A., Akl, M. R., Dragoi, A. M., Cardelli, J. A., & Sayed, K. A. E. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.04.043 · Cited by 27
Different growth and metastatic phenotypes associated with a cell-intrinsic change of Met in metastatic melanoma
Adachi, E., Sakai, K., Nishiuchi, T., Imamura, R., Sato, H., & Matsumoto, K. (2016) · Oncotarget · doi:10.18632/oncotarget.12221 · Cited by 27
Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
Choi, B., Cha, M., Eun, G. S., Lee, D. H., Lee, S., Ehsan, M., Chae, P. S., Heo, W. D., Park, Y., & Yoon, T. (2020) · eLife · doi:10.7554/elife.53934 · Cited by 27
Roles of circRNAs in cancer chemoresistance (Review)
Xin, C., Huang, F., Wang, J., Li, J., & Chen, Q. (2021) · Oncology Reports · doi:10.3892/or.2021.8176 · Cited by 27
A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy
Claus, J., Patel, G. S., Ng, T., & Parker, P. J. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140043 · Cited by 26
Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM
Rohrbeck, L., Gong, J., Lee, E. F., Kueh, A. J., Behren, A., Tai, L., Lessène, G., Huang, D. C. S., Fairlie, W. D., Strasser, A., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.96 · Cited by 27
Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma
Yang, H., Kircher, D. A., Kim, K., Grossmann, A. H., VanBrocklin, M. W., Holmen, S. L., & Robinson, J. P. (2017) · Oncogene · doi:10.1038/onc.2016.526 · Cited by 27
Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer
AHN, S. Y., Kim, J., KIM, M. A., Choi, J., & Kim, W. H. (2017) · Anticancer Research · doi:10.21873/anticanres.11426 · Cited by 26
Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma
Gao, M., Wang, H., Chen, X., Cao, W.-T., Li, F., Li, Y., Quan, H., Xie, C., & Lou, L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0020-z · Cited by 26
Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy
Li, Y., Dong, Q., & Cui, Y. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0137 · Cited by 25
Dabrafenib
Kainthla, R., Kim, K. B., & Falchook, G. S. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_14 · Cited by 27
PTEN regulates IGF ‐1R‐mediated therapy resistance in melanoma
Wang, J., Sinnberg, T. W., Niessner, H., Dölker, R., Sauer, B., Kempf, W. E., Meier, F. E., Leslie, N. R., & Schittek, B. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12390 · Cited by 26
Dabrafenib for treatment of BRAF-mutant melanoma
Falchook, G. S., Kainthla, R., & Kim, K. (2013) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s37220 · Cited by 28
Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Gridling, M., Ficarro, S. B., Breitwieser, F. P., Song, L., Parapatics, K., Colinge, J., Haura, E. B., Marto, J. A., Superti‐Furga, G., Bennett, K. L., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0152 · Cited by 26
Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation
Venukadasula, P. K. M., Owusu, B. Y., Bansal, N., Ross, L. J., Hobrath, J. V., Bao, D., Truss, J. W., Stackhouse, M. A., Messick, T. E., Klampfer, L., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00357 · Cited by 26
Epigenetic regulation of RTK signaling
Spangle, J. M., & Roberts, T. M. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1546-0 · Cited by 26
ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma
Capparelli, C., Purwin, T. J., Heilman, S. A., Chervoneva, I., McCue, P. A., Berger, A. C., Davies, M. A., Gershenwald, J. E., Krepler, C., & Aplin, A. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1001 · Cited by 27
The microenvironment and resistance to personalized cancer therapy
Masuda, S., & Belmonte, J. C. I. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.127-c1 · Cited by 26
Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy DevelopmentPreprint
Estape, A. A., Foggetti, G., Starrett, J. H., Nguyen, D. X., & Politi, K. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037820 · Cited by 23
ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells
Cruz-Gordillo, P., Honeywell, M. E., Harper, N. W., Leete, T., & Lee, M. J. (2020) · Science Signaling · doi:10.1126/scisignal.abb9820 · Cited by 24
Fluorescence resonance energy transfer based quantitative analysis of feedforward and feedback loops in epidermal growth factor receptor signaling and the sensitivity to molecular targeting drugs
Fujita, Y., Komatsu, N., Matsuda, M., & Aoki, K. (2014) · FEBS Journal · doi:10.1111/febs.12852 · Cited by 25
L’invasion des cellules tumorales
Albrengues, J., Meneguzzi, G., & Gaggioli, C. (2014) · médecine/sciences · doi:10.1051/medsci/20143004012 · Cited by 25
MAPK pathway inhibition in melanoma: resistance three ways
Wellbrock, C. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140020 · Cited by 29
Molecular Modeling of Exquisitely Selective c-Met Inhibitors through 3D-QSAR and Molecular Dynamics Simulations
Yuan, H., Zhuang, J., Hu, S., Li, H., Xu, J., Hu, Y., Xiong, X., Chen, Y., & Lu, T. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500268s · Cited by 25
The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells
Lyu, H., Yang, X. H., Edgerton, S. M., Thor, A. D., Wu, X., He, Z., & Liu, B. (2015) · Oncotarget · doi:10.18632/oncotarget.6404 · Cited by 25
Monocarboxylate transporter 1 contributes to growth factor-induced tumor cell migration independent of transporter activity
Gray, A. L., Coleman, D. T., Shi, R., & Cardelli, J. A. (2016) · Oncotarget · doi:10.18632/oncotarget.9016 · Cited by 25
Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets
Konstantakou, E. G., Velentzas, A. D., Anagnostopoulos, A. K., Litou, Z. I., Konstandi, O. A., Giannopoulou, A. F., Anastasiadou, E., Voutsinas, G. E., Tsangaris, G. T., & Stravopodis, D. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171512 · Cited by 26
Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance
Gonzalez-Martinez, D., Roth, L., Mumford, T. R., Guan, J., Le, A., Doebele, R. C., Huang, B., Tulpule, A., Niewiadomska–Bugaj, M., Bivona, T. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53451-7 · Cited by 24
Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC
Durrans, A., Gao, D., Gupta, R., Fischer, K. R., Choi, H., Rayes, T. E., Ryu, S., Nasar, A., Spinelli, C. F., Andrews, W. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129123 · Cited by 24
Major therapeutic developments and current challenges in advanced melanoma
Sullivan, R. J., & Flaherty, K. T. (2014) · British Journal of Dermatology · doi:10.1111/bjd.12698 · Cited by 24
BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases
Grigore, F., Yang, H., Hanson, N. D., VanBrocklin, M. W., Sarver, A. L., & Robinson, J. P. (2020) · Neoplasia · doi:10.1016/j.neo.2020.06.006 · Cited by 23
Targeting USP13 ‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancer
Giron, P., Eggermont, C., Noeparast, A., Vandenplas, H., Teugels, E., Forsyth, R. G., Wever, O. D., Aza‐Blanc, P., Gutierrez, G. J., & Grève, J. D. (2020) · International Journal of Cancer · doi:10.1002/ijc.33404 · Cited by 25
Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
Sachkova, A. A., Andreeva, D. V., Tikhomirov, A. S., Scherbakov, A. M., Salnikova, D. I., Sorokin, D. V., Bogdanov, F. B., Rysina, Y. D., Shchekotikhin, A. E., Shchegravina, E. S., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122829 · Cited by 24
AXL – a new player in resistance to HER2 blockade
Adam‐Artigues, A., Arenas, E. J., Arribas, J., Prat, A., & Cejalvo, J. M. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102639 · Cited by 24
Activation Status of the Pregnane X Receptor Influences Vemurafenib Availability in Humanized Mouse Models
MacLeod, A. K., McLaughlin, L. A., Henderson, C. J., & Wolf, C. R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1454 · Cited by 24
Polymerase I and Transcript Release Factor Acts As an Essential Modulator of Glioblastoma Chemoresistance
Wang, X., Liu, T., Bai, Y., Liao, H., Qiu, S., Chang, Z., Liu, Y., Yan, X., & Guo, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093439 · Cited by 24
cDNA microarray analysis of the effect of cantharidin on DNA damage, cell cycle and apoptosis-associated gene expression in NCI-H460 human lung cancer cells in vitro
Hsia, T., Yu, C.-C., Hsu, S., Tang, N.-Y., Lu, H., Yu, C.-S., Wu, S., LIN, J.-G., & Chung, J. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3538 · Cited by 25
Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF
Woo, J. K., Kang, J., Kim, B., Park, B. H., Shin, K.-J., Song, S.-W., Kim, J. J., Kim, H., Lee, S.-J., & Oh, S. H. (2015) · Oncotarget · doi:10.18632/oncotarget.4369 · Cited by 25
Growth-Factor-Driven Rescue to Receptor Tyrosine Kinase (RTK) Inhibitors through Akt and Erk Phosphorylation in Pediatric Low Grade Astrocytoma and Ependymoma
Sie, M., den Dunnen, W. F. A., Lourens, H. J., Boer, T. M.-D., Scherpen, F. J. G., Zomerman, W. W., Kampen, K. R., Hoving, E. W., & de Bont, E. S. J. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122555 · Cited by 25
JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2–Targeted Therapies
Manole, S., Richards, E. J., & Meyer, A. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0123 · Cited by 25
Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis
Lee, H., Lee, E., Yeo, S.-Y., Shin, S. H., Park, H., Nam, D., & Kim, S. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0547-8 · Cited by 24
p110α Inhibition Overcomes Stromal Cell–Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
Guan, J., Huang, D., Yakimchuk, K., & Okret, S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0784 · Cited by 25
Macroenvironment-gene-microenvironment interactions in ultraviolet radiation-induced melanomagenesis
Mo, X., Preston, S., & Zaidi, M. R. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.008 · Cited by 24
Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility
Li, R., Knight, J. F., Park, M., & Pendergast, A. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124960 · Cited by 24
DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma
Alam, S. K., Zhang, Y., Wang, L., Zhu, Z., Hernandez, C. E., Zhou, Y., Yang, N., Lei, J., Chen, X., Zeng, L., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02028-5 · Cited by 24
The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance
Miękus, K. (2016) · Oncology Reports · doi:10.3892/or.2016.5297 · Cited by 23
Metastatic melanoma moves on: translational science in the era of personalized medicine
Levesque, M. P., Cheng, P. F., Raaijmakers, M. I. G., Saltari, A., & Dummer, R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9658-0 · Cited by 23
Epigenetic suppression of PGC1α (PPARGC1A) causes collateral sensitivity to HMGCR-inhibitors within BRAF-treatment resistant melanomas
Liang, J., Yu, D., Luo, C., Bennett, C. F., Jedrychowski, M. P., Gygi, S. P., Widlund, H. R., & Puigserver, P. (2023) · Nature Communications · doi:10.1038/s41467-023-38968-7 · Cited by 23
Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma
Krepler, C., Xiao, M., Samanta, M., Vultur, A., Chen, H., Brafford, P. A., Reyes-Uribe, P. I., Halloran, M. B., Chen, T., He, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12078 · Cited by 23
Phosphoproteome Profiling Reveals Molecular Mechanisms of Growth-Factor-Mediated Kinase Inhibitor Resistance in EGFR-Overexpressing Cancer Cells
Koch, H., Wilhelm, M., Ruprecht, B., Beck, S., Frejno, M., Klaeger, S., & Küster, B. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00621 · Cited by 22
Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition
Sharma, R., Smalley, I., Spence, P., Sondak, V. K., Smalley, K. S. M., & Koomen, J. M. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00613 · Cited by 21
MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models
Fiedler, U., Ekawardhani, S., Cornelius, A., Gilboy, P., Bakker, T. R., Dolado, I., Stumpp, M. T., & Dawson, K. M. (2017) · Oncotarget · doi:10.18632/oncotarget.21738 · Cited by 23
Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors
Andey, T. A., Bora-Singhal, N., Chellappan, S., & Singh, M. S. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.02.007 · Cited by 23
Case History
Cui, J. J., McTigue, M. A., Kania, R. S., & Edwards, M. P. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00025-9 · Cited by 23
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer
Momeny, M., Tienhaara, M., Sharma, M., Chakroborty, D., Varjus, R., Takala, I., Merisaari, J., Padzik, A., Vogt, A., Paatero, I., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00088-0 · Cited by 24
HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
Penuel, E. M., Li, C., Parab, V. Y., Burton, L., Cowan, K. J., Merchant, M. A., Yauch, R. L., Patel, P. H., Peterson, A., Hampton, G. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0015 · Cited by 22
Multiplexed Analysis for Anti-Epidermal Growth Factor Receptor Tumor Cell Growth Inhibition Based on Quantum Dot Probes
Ren, D., Xia, Y., Wang, B., & You, Z. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04471 · Cited by 22
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
Ma, R., Xu, L., Qu, X., Che, X., Zhang, Y., Fan, Y., Li, C., Guo, T., Hou, K., Hu, X., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0086-x · Cited by 22
Targeted drug combination therapy design based on driver genes
Zsákai, L., Sipos, A., Dobos, J., Erös, D., Szántai-Kis, C., Bánhegyi, P., Pató, J., Őrfi, L., Matula, Z., Mikala, G., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26985 · Cited by 22
Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors
Heynen, G. J. J. E., Lisek, K., Vogel, R., Wulf-Goldenberg, A., Alcaniz, J., Montaudon, É., Marangoni, E., & Birchmeier, W. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01521-3 · Cited by 23
NF-κB Regulation of c-FLIP Promotes TNFα-Mediated RAF Inhibitor Resistance in Melanoma
Shao, Y., Le, K., Cheng, H., & Aplin, A. E. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.91 · Cited by 22
Braf V600E mutation in melanoma: translational current scenario
Guadarrama-Orozco, J. A., Ortega-Gómez, A., Ruíz‐García, E., la Vega, H. A., Meneses-García, A. A., & López‐Camarillo, C. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1469-6 · Cited by 22
The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor
Mohyeldin, M. M., Akl, M. R., Ebrahim, H. Y., Dragoi, A. M., Dykes, S. S., Cardelli, J. A., & Sayed, K. A. E. (2016) · Oncotarget · doi:10.18632/oncotarget.8681 · Cited by 22
89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment
Pool, M., Kol, A., de Jong, S., de Vries, E. G. E., Hooge, M. N. L., & van Scheltinga, A. G. T. T. (2017) · mAbs · doi:10.1080/19420862.2017.1371382 · Cited by 22
Leveraging and manufacturing in vitro multicellular spheroid-based tumor cell model as a preclinical tool for translating dysregulated tumor metabolism into clinical targets and biomarkers
Wang, T., Wang, L., Wang, G., & Zhuang, Y. (2020) · Bioresources and Bioprocessing · doi:10.1186/s40643-020-00325-7 · Cited by 21
BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature
Guerrero, P., Albarrán, V., San Román, M., González-Merino, C., García de Quevedo, C., Moreno, J., Calvo, J. C., González, G., Orejana, I., Chamorro, J., et al. (2023) · Cancers · doi:10.3390/cancers15215243 · Cited by 21
Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas
Wu, Z., Bai, F., Fan, L., Pang, W., Han, R., Wang, J., Liu, Y., Xia, Y., Duan, H., & Xing, L. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.08.014 · Cited by 21
From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures
Tseng, Y., & Boehm, J. S. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.007 · Cited by 21
Extracellular Vesicles-Based Cell-Cell Communication in Melanoma: New Perspectives in Diagnostics and Therapy
Kluszczyńska, K., & Czyż, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020965 · Cited by 22
Mesoporous nanodrug delivery system: a powerful tool for a new paradigm of remodeling of the tumor microenvironment
Hang, Y., Liu, Y., Teng, Z., Cao, X., & Zhu, H. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01841-2 · Cited by 22
Evaluating the Promiscuous Nature of Tyrosine Kinase Inhibitors Assessed in A431 Epidermoid Carcinoma Cells by Both Chemical- and Phosphoproteomics
Giansanti, P., Preisinger, C., Huber, K., Gridling, M., Superti‐Furga, G., Bennett, K. L., & Heck, A. J. R. (2014) · ACS Chemical Biology · doi:10.1021/cb500116c · Cited by 21
Resistance to targeted cancer drugs through hepatocyte growth factor signaling
Heynen, G. J. J. E., Fonfara, A., & Bernards, R. (2014) · Cell Cycle · doi:10.4161/15384101.2014.988033 · Cited by 21
Hyaluronic Acid Layered Chimeric Nanoparticles: Targeting MAPK-PI3K Signaling Hub in Colon Cancer Cells
Palvai, S., Kuman, M. M., Sengupta, P., & Basu, S. (2017) · ACS Omega · doi:10.1021/acsomega.7b01315 · Cited by 21
Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Das, T. K., Esernio, J., & Cagan, R. L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2001 · Cited by 21
Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment
Widodo, S. S., Hutchinson, R. A., Fang, Y., Mangiola, S., Neeson, P. J., Darcy, P. K., Barrow, A. D., Hovens, C. M., Dinevska, M., Stylli, S. S., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02801-7 · Cited by 20
Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities
Jonas, O. H., Oudin, M. J., Kosciuk, T., Whitman, M. A., Gertler, F. B., Cima, M. J., Flaherty, K. T., & Langer, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2722 · Cited by 21
Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines
Jastrzebski, K., Thijssen, B., Kluin, R. J. C., de Lint, K., Majewski, I. J., Beijersbergen, R. L., & Wessels, L. F. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2698 · Cited by 21
Role of the MEK Inhibitor Trametinib in the Treatment of Metastatic Melanoma
King, J., & Nathan, P. (2014) · Future Oncology · doi:10.2217/fon.14.89 · Cited by 21
The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness
Ha, J. R., Siegel, P. M., & Ursini‐Siegel, J. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25561 · Cited by 20
Role of mTOR As an Essential Kinase in SCLC
Kern, J. A., Kim, J., Foster, D. G., Mishra, R., Gardner, E. E., Poirier, J. T., Rivard, C. J., Yu, H., Finigan, J. H., Dowlati, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.026 · Cited by 20
Exosomal long non-coding RNAs: novel molecules in gastrointestinal cancers’ progression and diagnosis
Roshani, M., Baniebrahimi, G., Mousavi, M., Zare, N., Sadeghi, R., Salarinia, R., Sheida, A., Molavizadeh, D., Sadeghi, S., Moammer, F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1014949 · Cited by 20

Authors: Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., Ribas, A., Li, J., Moffat, J., Sutherlin, D. P., Koeppen, H., Merchant, M., Neve, R., & Settleman, J.
Affiliations: Genentech (US)
Vanderbilt University Medical Center (US)
University of California, Los Angeles (US)
Corresponding author: Settleman, Jeff
ORCID: Wilson, Timothy R.
Penuel, Elicia
Chan, Emily
Peng, Jing
Lin, Eva
Wang, Yulei
Ribas, Antoni
Koeppen, Hartmut
Merchant, Mark
Neve, Richard
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2012-07
Volume: 487
Issue: 7408
Pages: 505-509
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature11249
PMC: PMC3724525
OpenAlex: W1999025555
Cited by: 1,134
References: 29
Citations by year: 2026: 23 · 2025: 16 · 2024: 31 · 2023: 46 · 2022: 47 · 2021: 51 · 2020: 65 · 2019: 70 · 2018: 85 · 2017: 87 · 2016: 125 · 2015: 137 · 2014: 166 · 2013: 150 · 2012: 34
FWCI: 62.91
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: National Cancer Institute (K24CA097588)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords: drug resistance, kinase inhibitors, receptor tyrosine kinase, growth factors, hepatocyte growth factor, BRAF inhibitors, vemurafenib, melanoma, tumor microenvironment, phosphatidylinositol 3-kinase, mitogen-activated protein kinase, combination therapy
MeSH terms: Lapatinib, Vemurafenib, Antineoplastic Agents, Breast Neoplasms, Cell Survival, Female, Humans, Indoles, Ligands, Melanoma, Quinazolines, Sulfonamides, Signal Transduction, Hepatocyte Growth Factor, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Receptor Protein-Tyrosine Kinases, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks